10 completed, 3 active not recruiting, 3 recruiting, 3 terminated. 13 Phase 2, 12 Phase 1, 1 Not applicable.
Follow Recurrent Colorectal Carcinoma: new trials by email Literature Review of Recurrent Colorectal Carcinoma trials Research Report on Recurrent Colorectal Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) Biopsy, Pembrolizumab, Therapeutic Autologous Dendritic Cells - Metastatic Microsatellite Stable Colorectal Carcinoma, Recurrent Colorectal Carcinoma | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2024-10-01 | 2024-09-26 | |
| Molecular Study and Precision Medicine for Colorectal Cancer Molecular Profiling & drug testing in tumor organoids and PDXs - Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 100 | 2024-10-01 | 2024-07-24 | |
| Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer Aminolevulinic Acid, Biospecimen Collection, Computed Tomography - Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma | Phase 1 / Phase 2 | Recruiting | Roswell Park Cancer Institute | 21 | 2024-07-30 | 2026-10-15 |
| Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform Biospecimen Collection, Tissue Collection - Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma | Recruiting | Mayo Clinic | 324 | 2024-04-24 | 2026-03-12 | |
| LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer Abemaciclib, Cetuximab, ERK1/2 Inhibitor LY3214996 - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 46 | 2020-12-02 | 2026-10-05 |
| Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer Cetuximab, Encorafenib, Nivolumab - BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 38 | 2019-06-14 | 2026-06-11 |
| Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia rhTPO, irinotecan, Raltitrexed - Recurrent Colorectal Carcinoma, Thrombopenia | Phase 2 | Unknown | Fudan University | 50 | 2019-02-01 | 2019-01-30 |
| Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver Celecoxib, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b - Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 19 | 2018-04-19 | 2022-03-02 |
| Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer Atezolizumab, Bevacizumab, Capecitabine - Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma | Phase 2 | Completed | Academic and Community Cancer Research United | 133 | 2017-07-07 | 2024-08-23 |
| Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer XL888, Pembrolizumab - Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Completed | Emory University | 47 | 2017-07-07 | 2026-05-22 |
| APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401 - Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm | Phase 1 | Completed | Wake Forest University Health Sciences | 11 | 2017-04-28 | 2024-10-10 |
| Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery Chemotherapy, Laboratory Biomarker Analysis, Metastasectomy - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver | Phase 2 | Terminated | M.D. Anderson Cancer Center | 29 | 2016-09-23 | 2026-02-17 |
| Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery Cetuximab, Laboratory Biomarker Analysis, Pembrolizumab - Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer | Phase 1 / Phase 2 | Completed | Roswell Park Cancer Institute | 45 | 2016-08-05 | 2022-10-06 |
| FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis - Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer | Phase 2 | Terminated | City of Hope Medical Center | 1 | 2016-02-16 | 2018-08-16 |
| TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim - Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Terminated | Mayo Clinic | 4 | 2016-02-05 | 2018-09-05 |
| Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas SGM-101 - Colon Cancer, Rectum Cancer | Phase 1 / Phase 2 | Completed | Surgimab | 75 | 2016-01-01 | 2019-07-18 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-26 |
| Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer Cyclosporine, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Colorectal Carcinoma, Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2014-08-29 | 2025-02-11 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Pharmacological Study, Romidepsin - Glioma, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 37 | 2012-08-03 | 2025-02-07 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 1 | Completed | Roswell Park Cancer Institute | 18 | 2012-03-01 | 2016-10-04 |
Showing 20 of 22. Sign in to see all of them.
Colorectal Neoplasms (22) · Pancreatic Neoplasms (6) · Carcinoma, Renal Cell (5) · Breast Neoplasms (4) · Colonic Neoplasms (4) · Melanoma (4) · Neoplasm Metastasis (4) · Rectal Neoplasms (4) · Carcinoma, Hepatocellular (3) · Esophageal Neoplasms (3) · Lung Neoplasms (3) · Prostatic Neoplasms (3) · Urinary Bladder Neoplasms (3) · Brain Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2)
Colonic Diseases (22) · Digestive System Diseases (22) · Digestive System Neoplasms (22) · Gastrointestinal Diseases (22) · Gastrointestinal Neoplasms (22) · Intestinal Diseases (22) · Intestinal Neoplasms (22) · Neoplasms by Site (22) · Rectal Diseases (22) · Neoplasms (20) · Endocrine Gland Neoplasms (8) · Endocrine System Diseases (8) · Neoplasms by Histologic Type (7) · Neoplasms, Glandular and Epithelial (7) · Pancreatic Diseases (7)
Cetuximab (4) · Irinotecan (3) · Specimen Handling (3) · pembrolizumab (3) · Biopsy (2) · Disulfides (2) · Immunoglobulin G (2) · Magnetic Resonance Spectroscopy (2) · Nivolumab (2) · 1-phenyl-3,3-dimethyltriazene (1) · 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1) · 2C4 antibody (1) · AZD 6244 (1) · AZD4547 (1) · Ado-Trastuzumab Emtansine (1)
Roswell Park Cancer Institute (5) · M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (3) · Mayo Clinic (2) · Academic and Community Cancer Research United (1) · City of Hope Medical Center (1) · Emory University (1) · Fudan University (1) · HiberCell, Inc. (1) · Surgimab (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · Wake Forest University Health Sciences (1)
United States (18) · Canada (2) · China (1) · Guam (1) · Netherlands (1) · Philippines (1) · Puerto Rico (1)
Alexander L Vahrmeijer, MD, PhD (1) · Anthony S Dakwar (1) · Christine M Parseghian, MD (1) · Christopher H Lieu (1) · Christos Fountzilas (1) · Dev Mukhopadhyay, PhD (1) · Gerardo Cornelio, MD, FPCP/FPS (1) · Keith T Flaherty (1) · Kunle Odunsi (1) · Ma. Belen Tamayo, MD (1) · Maria Diab, MD (1) · Marwan Fakih (1) · Niharika Mettu (1) · Peter Cohen (1) · Pierre Triozzi (1)
PMID 26586415, PMID 29361435, PMID 31960953, PMID 32416765, PMID 32463741, PMID 33048619, PMID 35133871, PMID 35138919, PMID 35179586, PMID 35362047, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39863139, PMID 39913886, PMID 40132910, PMID 40791544, PMID 40865033, PMID 41066729, PMID 41484629, PMID 41793309
P30CA015083 (2), P30CA016056 (2), UM1CA186644 (2), UM1CA186686 (2), UM1CA186690 (2), UM1CA186716 (2), UM1CA186717 (2), K23CA190849 (1), P01CA234212 (1), P30CA012197 (1), P30CA016672 (1), P30CA138292 (1), R01CA158318 (1), R01CA177996 (1), R01CA187238 (1)